UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents

Journal of thrombosis and haemostasis, 2018-08, Vol.16 (8), p.1580-1591

2018

Volltextzugriff (PDF)

IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2009-10, Vol.7 (10), p.1703-1710

2009

Volltextzugriff (PDF)

Comparative analysis of marketed factor VIII products: reply

Journal of thrombosis and haemostasis, 2019-01, Vol.17 (1), p.233-235

2019

Volltextzugriff (PDF)

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Journal of thrombosis and haemostasis, 2011-05, Vol.9 (5), p.936-944

2011

Volltextzugriff (PDF)

Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS‐13 activity levels in inhibitor‐treated rats by the use of defined doses of recombinant ADAMTS‐13

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2053-2062

2015

Volltextzugriff (PDF)

Structure-activity relationship of the pro- and anticoagulant effects of Fucus vesiculosus fucoidan

Thrombosis and haemostasis, 2014, Vol.111 (3), p.429-437

2014

Volltextzugriff (PDF)

In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications

Journal of thrombosis and haemostasis, 2018-08, Vol.16 (8), p.1592-1603

2018

Volltextzugriff (PDF)

Inhibition of tissue factor:factor VIIa–catalyzed factor IX and factor X activation by TFPI and TFPI constructs

Journal of thrombosis and haemostasis, 2014-11, Vol.12 (11), p.1826-1837

2014

Volltextzugriff (PDF)

Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles

Journal of thrombosis and haemostasis, 2018-06, Vol.16 (6), p.1176-1181

2018

Volltextzugriff (PDF)

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 (1), p.58-63

2015

Volltextzugriff (PDF)

Disulfide bond reduction of von Willebrand factor by ADAMTS‐13

Journal of thrombosis and haemostasis, 2010-12, Vol.8 (12), p.2778-2788

2010

Volltextzugriff (PDF)

Direct inhibition of factor VIIa by TFPI and TFPI constructs

Journal of thrombosis and haemostasis, 2013-04, Vol.11 (4), p.704-714

2013

Volltextzugriff (PDF)

Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2016-07, Vol.14 (7), p.1410-1419

2016

Volltextzugriff (PDF)

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein

Journal of thrombosis and haemostasis, 2013-06, Vol.11 (6), p.1137-1145

2013

Volltextzugriff (PDF)

VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

Journal of thrombosis and haemostasis, 2009-03, Vol.7 (3), p.421-428

2009

Volltextzugriff (PDF)

The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses

Virology (New York, N.Y.), 1998-05, Vol.244 (2), p.365-396

1998

Volltextzugriff (PDF)

Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α

Journal of thrombosis and haemostasis, 2015-01, Vol.13 (1), p.92-100

2015

Volltextzugriff (PDF)

811: Fully human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) exhibit anti-cancer activity in animal models

European journal of cancer (1990), 2014-07, Vol.50, p.S196-S196

2014

Volltextzugriff (PDF)

674: Oxidized macrophage migration inhibitory factor (oxMIF) occurs specifically in malignant tissue and is a potential new drug target and biomarker in cancer

European journal of cancer (1990), 2014-07, Vol.50, p.S163-S163

2014

Volltextzugriff (PDF)

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation

Hämostaseologie, 2012, Vol.32 Suppl 1 (S 01), p.S29-S38

2012

Volltextzugriff (PDF)

818: Human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) synergize with chemotherapeutic agents in animal models of cancer

European journal of cancer (1990), 2014-07, Vol.50, p.S198-S198

2014

Volltextzugriff (PDF)

Increased ADAMTS‐13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo

Journal of thrombosis and haemostasis, 2006-05, Vol.4 (5), p.1063-1070

2006

Volltextzugriff (PDF)

A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay

Journal of thrombosis and haemostasis, 2014-09, Vol.12 (9), p.1523-1532

2014

Volltextzugriff (PDF)

ADAMTS13-mediated thrombolysis of t-PA–resistant occlusions in ischemic stroke in mice

Blood, 2016-05, Vol.127 (19), p.2337-2345

2016

Volltextzugriff (PDF)

Factor IX mutants with enhanced catalytic activity

Journal of thrombosis and haemostasis, 2009-10, Vol.7 (10), p.1656-1662

2009

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(91)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Life Sciences & Biomedicine
(65)
Humans
(53)
Hematology
(47)
Adamts13 Protein
(30)
Animals
(27)
Biological And Medical Sciences
(24)
Cardiovascular System & Cardiology
(24)
Peripheral Vascular Disease
(24)
Male
(19)
Medical Sciences
(16)
Female
(13)
Mice
(13)
Hematologic And Hematopoietic Diseases
(12)
Adam Proteins
(11)
Adam Proteins - Immunology
(11)
Platelet Diseases And Coagulopathies
(11)
Purpura, Thrombotic Thrombocytopenic - Immunology
(11)
Adult
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents

IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura

Comparative analysis of marketed factor VIII products: reply

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS‐13 activity levels in inhibitor‐treated rats by the use of defined doses of recombinant ADAMTS‐13

Structure-activity relationship of the pro- and anticoagulant effects of Fucus vesiculosus fucoidan

In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications

Inhibition of tissue factor:factor VIIa–catalyzed factor IX and factor X activation by TFPI and TFPI constructs

Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

Disulfide bond reduction of von Willebrand factor by ADAMTS‐13

Direct inhibition of factor VIIa by TFPI and TFPI constructs

Preclinical assessment of a new recombinant ADAMTS‐13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein

VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses

Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α

811: Fully human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) exhibit anti-cancer activity in animal models

674: Oxidized macrophage migration inhibitory factor (oxMIF) occurs specifically in malignant tissue and is a potential new drug target and biomarker in cancer

BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation

818: Human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) synergize with chemotherapeutic agents in animal models of cancer

Increased ADAMTS‐13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo

A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay

ADAMTS13-mediated thrombolysis of t-PA–resistant occlusions in ischemic stroke in mice

Factor IX mutants with enhanced catalytic activity

Suchergebnisse filtern